Além disso, fortes evidências agora apoiam um papel para a inibição da GSK-3 mediando o poro de transição da permeabilidade mitocondrial no mecanismo de proteção do pré-condicionamento isquêmico. No ...
GSK PLC GSK shares rallied 1.06% to £13.34 Monday, on what proved to be an all-around favorable trading session for the stock ...
GSK said on Friday the addition of its cancer drug Jemperli to both standard of care chemotherapy and Zejula maintenance ...
Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a price target of ...
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...
Partnering with GSIS Museo ng Sining, the commission celebrated the launch with a lecture and talk-back program as well as ...
Advertisers were expected to spend a record-breaking 10.5 billion British pounds during the Christmas season of 2024, marking a nearly eight percent increase from the previous year's record ...
GSK’sGSK-0.34%decrease; red down pointing triangle blood-cancer drug Blenrep showed positive overall survival data in a late-stage trial, increasing the likelihood for the treatment to return to ...
GSK is now looking to start a phase 3 trial in the first-line setting shortly, Abdullah said. The DREAMM-10 study will once again pit Blenrep against Darzalex, this time as part of front-line ...
LONDON — A blood cancer treatment from GSK helped patients live longer in a pivotal trial, a significant finding as the once-withdrawn drug mounts a comeback. In the study, a treatment ...
Cambridge-based AstraZeneca and London-based GSK (formerly GlaxoSmithKline) are the two flagships of the British drug manufacturing industry. For several years, GSK was the leading pharmaceutical ...
The Blenrep comeback continues for GSK. The blood cancer treatment, which was once pulled off the market, was found to help patients live longer in a Phase 3 clinical trial, the results of which were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback